Polygynax is commonly used to help with symptoms that may appear suddenly or intensify over time in adult women. Relevant conditions include the local management of vaginitis due to sensitive germs, such as bacterial vaginitis, vulvo-vaginitis due to Candida species, and mixed vaginitis. The primary areas of use are associated with these conditions. The medication is used in situations involving certain distressing symptoms that interfere with daily functioning, such as intense vaginal itching (pruritus), local burning, irritation, and abnormal vaginal discharge (leucorrhoea).

Therapeutic Focus and Patient Support

The use of this medication helps address symptom clusters that may appear suddenly or intensify over time in conditions presenting with significant symptomatic burden. This commonly used approach contributes to improved comfort during symptomatic periods and assists with maintaining functional stability. Furthermore, it is commonly used in contexts involving heightened systemic burden, such as pre- or post-gynecological procedures, where additional symptomatic support is needed.

“Applied during phases of increased distress or discomfort, the medication is applied to help manage the intensity of these manifestations.”

---

Quick Fact: Relief for Mixed Infectious Symptoms This medication is often used to provide support in infections where multiple organisms contribute to the symptomatic burden, helping to ease the overall symptom load during acute episodes.

Regulatory References

1. Malta Medicines Authority (a European regulatory body)

The official regulatory documents establish strict criteria for who is eligible to use Polygynax (Полижинакс), focusing primarily on adult women and prohibiting use in specific populations and conditions.

Eligibility Scope

Category	Regulatory Status
Populations for whom use is allowed	Adult Women (for local intravaginal treatment).
Populations for whom use is not recommended	Pregnant and Lactating Women; generally not advised due to the risk of systemic absorption of Neomycin, which carries a theoretical ototoxic risk to the fetus or newborn.
Populations for whom use is contraindicated	Individuals with known hypersensitivity to Neomycin, Polymyxin B, Nystatin, or excipients, including allergy to peanut or soya.
Age-related eligibility rules	Use is limited to Adults; use in children and adolescents is not applicable or not established.
Condition-specific eligibility rules	Conditional Caution is required for patients with renal insufficiency, as there is an increased risk of systemic effects from the antibiotic components with prolonged use.
Eligibility-related restrictions	Use is contraindicated with polyurethane male condoms, female condoms, or diaphragms, as excipients may cause product rupture. Concomitant use with spermicidal products is not recommended due to potential inactivation.

Connection to the Overall Eligibility Profile

The regulatory profile strictly defines eligibility through absolute contraindications based on allergic risk and the potential for material damage to contraceptive barriers. Use is formally restricted by age and physiological status, excluding children and generally not recommending the medication for women who are pregnant or breastfeeding.

Interactions with other medicines and products

The official interaction profile for Polygynax is narrowly defined by its local, intravaginal route of administration, resulting in restrictions focused primarily on minimizing device failure and local product inactivation.

Interaction Restrictions for Local Products

Co-administration is subject to formal restrictions with specific physical barrier contraceptives and local chemical agents, classified as follows in regulatory documents.

Restriction Type	Interacting Product(s)	Official Interaction Outcome
Contraindicated	Polyurethane male condoms, female condoms, and diaphragms	Risk of rupture or structural degradation of the contraceptive barrier due to the oily excipients in the vaginal capsule.
Not Recommended	Spermicidal products (local contraceptives)	Local vaginal treatment is documented to be likely to invalidate the specific contraceptive action of the spermicide.

Caution for Impaired Renal Function

Despite the negligible systemic absorption typically associated with this formulation, regulatory documentation includes a population-specific caution. The risk of systemic toxic effects, specifically impacting auditory and renal function, cannot be definitively excluded in patients with renal insufficiency (impaired kidney function). This warning relates to the components Neomycin and Polymyxin B and acknowledges a potential concern for accumulation if clearance is compromised or if systemic absorption were to occur. This is the only population-dependent interaction consideration stated in the official labels.

How Полижинакс Works: Mechanism of Action

Destruction of Microbial Cell Membranes

The drug employs the antibiotic Polymyxin B and the antifungal Nystatin to physically compromise the cell envelopes of susceptible microorganisms. Polymyxin B disrupts the Lipopolysaccharide (LPS) layer of bacteria, while Nystatin binds to the Ergosterol in fungal membranes. Both actions result in the formation of pores, causing the catastrophic loss of cellular homeostasis and rapid cell death.

Inhibition of Bacterial Protein Synthesis

The active ingredient Neomycin provides a second, distinct antibacterial mechanism by targeting the bacteria's genetic machinery. It binds irreversibly to the 30S ribosomal subunit, which fatally inhibits the protein synthesis pathway by causing errors in mRNA translation. This production of non-functional proteins leads to the metabolic collapse and subsequent death of susceptible bacterial cells.

Broad-Spectrum Mechanistic Complementarity

The co-formulation utilizes a broad mechanistic synergy by simultaneously addressing both susceptible bacterial (via ribosomal inhibition and membrane disruption) and fungal microorganisms (via membrane pore formation). This strategy allows for a broad cytotoxic effect against the local microbial population, leading to the physiological effect of local microbial population clearance.

Official Administration Guidelines

Polygynax is formulated as a soft vaginal capsule containing the combination of Neomycin, Polymyxin B, and Nystatin, and is strictly administered via the intravaginal route. The capsule is designed exclusively for localized delivery and must not be swallowed under any circumstances. The medicine is reserved for adults only, as specific administration rules for pediatric patients are not detailed in the official prescribing information.

Dosing and Treatment Course

The standard regimen specifies the use of one vaginal capsule per administration. This single dose is scheduled to be administered once daily, with the prescribed timing being in the evening at bedtime, which facilitates localized retention during a period of rest.

The established duration for the full course of treatment is 12 consecutive days. This procedural course must not be discontinued even if the patient experiences a menstrual period during the treatment cycle.

Procedural Administration

For proper use, the capsule should be introduced deep into the vagina, preferably while the patient is in a lying down position to aid placement. As part of the standard administration protocol, patients are officially advised to avoid the use of vaginal douches or tampons during the entire 12-day period, supporting the localized action of the formulation.

Research Evidence / Overview of Studies for Полижинакс (Polygynax)

---

Evidence for Empirical Treatment of Vaginitis

Research into this medication was studied for use in women experiencing symptoms of infectious vaginitis, particularly when the exact bacterial or fungal cause was not yet identified. The main evidence comes from large, international Randomized Controlled Trials (RCTs). These RCTs research examined clinical success rates, using a single-agent antifungal as the comparison. The studies were used in research examining how symptoms change over time, focusing on patient-reported outcomes describing perceived discomfort related to vaginal burning, itching (pruritus), and discharge.

The principal comparative study reported measurements related to clinical success being numerically higher in the combination group than in the single-agent comparison group. The difference between these two groups on the main measure of overall clinical success was reported to be close to the threshold for achieving statistical significance (the scientific definition of certainty). Secondary analyses described patterns regarding certain symptoms, such as burning and discharge, with measured changes observed in the combination group and the comparator over a defined period.

Research on Microbiologically Confirmed Mixed Vaginitis

The research for this indication involves studies that specifically evaluated the triple-combination product in patients with a confirmed diagnosis of infection caused by both susceptible bacteria and/or Candida species. This research primarily relies on open-label clinical studies and observational settings evaluating daily-life functioning. The studies monitored microbiological outcomes (the clearance or reduction of the studied pathogens) and clinical assessment of symptomatic recovery.

Studies reported how symptoms evolved in the observed populations, with a percentage of patients being assessed as free of the studied pathogens at the post-treatment follow-up check. Since much of this research is older and comparative evidence is lacking, the overall evidence quality varies across studies.

---

What is Still Uncertain About the Research Base

A key research limitation is the lack of extensive study on long-term recurrence rates. Because long-term effects are not fully established, the evidence contributes to understanding symptom patterns over short intervals but is limited in data on long-term recurrence patterns. The overall evidence base is built upon studies that span several decades, and a significant gap exists in high-quality, contemporary comparative evidence that rigorously tests the combination against single-agent alternatives across diverse patient groups. Findings research provides context but not individual predictions about how an individual's symptoms may evolve over time.

Key Studies & References

1. PACKAGE LEAFLET: INFORMATION FOR THE USER POLYGYNAX, vaginal capsule (Regulatory Document / Summary of Product Characteristics)
2. POLYGYNAX and POLYGYNAX VIRGO (neomycin, polymyxin B, nystatin) - Low clinical benefit in the local treatment of vaginitis (French Health Authority HAS Assessment)

Common questions about Полижинакс (FAQ)

Q: What is the difference between Polygynax and other suppositories for thrush?

Official documents describe this product as a triple-combination local anti-infective. It contains a unique combination of three active components: two antibiotics (Neomycin and Polymyxin B) and one antifungal agent (Nystatin). This specific combination of active components distinguishes its documented approach.

Q: Is it true that Polygynax treats more than just thrush?

Official information states the product is indicated for the local management of infections caused by both susceptible bacteria and/or fungi. This dual action capability means it is used to address a condition often described as mixed vaginitis, which involves both types of pathogens.

Q: Why does Polygynax have an oily base?

The formulation contains oily excipients (inactive ingredients). Regulatory documents note the presence of these oily substances as the reason for the risk of degradation with certain latex or polyurethane contraceptives. The formulation contains oily excipients, which are essential to the capsule's designed delivery system.

Q: How does Polygynax affect barrier contraceptives like condoms?

Official information states that the product is contraindicated for use with specific physical barrier contraceptives, including polyurethane male condoms, female condoms, and diaphragms. This restriction is due to the oily excipients, which are described as potentially causing structural degradation or rupture of the contraceptive barrier.

Q: Is there a limit to the duration of the Polygynax treatment course?

The established duration for the full course of treatment is 12 consecutive days. Regulatory warnings note that prolonged or excessive administration carries a heightened risk of systemic toxic effects, such as toxicity to the kidneys or hearing, and is also associated with local allergic skin reactions.

Q: Is Polygynax available without a prescription?

Official regulatory labeling classifies this product as a prescription-only medicine (POM). This means dispensation requires a valid prescription from a licensed healthcare professional.

Q: Does Polygynax contain hormones?

No. Official documents list the active ingredients as Neomycin sulfate, Polymyxin B sulfate, and Nystatin. The product is categorized as a local anti-infective and antiseptic, and its formulation does not include any hormonal components.

Q: What is the likelihood of infection recurrence after using Polygynax?

According to the research overview in regulatory documents, the official evidence base is limited in data on long-term recurrence patterns. Therefore, studies do not provide individual predictions about the likelihood of infection recurrence over extended periods.

Q: Why doesn't the official instruction contain detailed guidance on combining it with alcohol?

Official regulatory documents state that the interaction of the product with food, drink, and alcohol is Not Applicable. Since the product is administered locally and systemic absorption is minimal, specific warnings regarding standard consumption of alcohol are not deemed necessary in the labeling.

Q: Does Polygynax have a cumulative effect?

While the drug is intended for local use, official safety information documents the potential for systemic toxic effects (specifically on hearing and kidney function). This risk is associated with prolonged or excessive administration, as documented systemic toxic effects relate to the potential accumulation of antibiotic components.

Q: Does the partner need treatment if I use Polygynax?

Official documents suggest that the treatment of the sexual partner may be considered by a doctor to help avoid reinfection. Official documents state that the consideration of partner treatment is typically handled by a healthcare professional.

Q: Can Polygynax be used for treating vaginitis in adolescent girls?

Regulatory documents state that the use of this specific product is limited to adults. The medication is officially documented as not applicable or not established for use in children and adolescents.

Q: Is it true that the drug can cause addiction?

No. Based on its pharmacological classification as a local anti-infective and the nature of its active ingredients, the product is not associated with an abuse or addiction potential in regulatory documents.

Q: What safety concerns are linked to long-term use of Polygynax?

Regulatory safety information warns that contact allergic eczema is associated with long-term use. Additionally, the risk of systemic toxic effects is also increased with prolonged administration. These risks are why a limited duration of treatment is recommended in the official guidelines.

Storage and Disposal Requirements for Polygynax (Полижинакс)

---

Official Storage Conditions

Polygynax vaginal capsules must be stored at a temperature not exceeding 25 C. This product is intended for ambient storage, and should not be used after the expiry date printed on the packaging.

Protection and Packaging

• The medicine must be kept out of the sight and reach of children.
• The product must be stored in its original package to ensure protection and stability.

Disposal Instructions

Official regulatory guidelines require specific procedures for discarding unused or expired medication. Polygynax must not be disposed of via wastewater or ordinary household waste. Instead, the user must ask a pharmacist how to dispose of any medicine that is no longer required.